{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T22:22:35Z","timestamp":1773699755422,"version":"3.50.1"},"reference-count":37,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82003808"],"award-info":[{"award-number":["82003808"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical Pharmacology"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.bcp.2025.117434","type":"journal-article","created":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T19:47:08Z","timestamp":1760730428000},"page":"117434","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"P4","title":["Phospholipase D2 regulation by transcription factor FOXA1 promotes the drug resistance of vemurafenib in melanoma cells"],"prefix":"10.1016","volume":"242","author":[{"given":"Jun","family":"Liu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lingjun","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cheng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chenjie","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jinkang","family":"He","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pengcheng","family":"Ma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9014-7502","authenticated-orcid":false,"given":"Hongyang","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bcp.2025.117434_b0005","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2024.104276","article-title":"The treatment of advanced melanoma: current approaches and new challenges","volume":"196","author":"Boutros","year":"2024","journal-title":"Crit. Rev. Oncol. Hematol."},{"issue":"5","key":"10.1016\/j.bcp.2025.117434_b0010","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1001\/jamadermatol.2022.0160","article-title":"Global burden of cutaneous melanoma in 2020 and projections to 2040","volume":"158","author":"Arnold","year":"2022","journal-title":"JAMA Dermatol."},{"issue":"2","key":"10.1016\/j.bcp.2025.117434_b0015","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.cell.2012.06.024","article-title":"A landscape of driver mutations in melanoma","volume":"150","author":"Hodis","year":"2012","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.bcp.2025.117434_b0020","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1159\/000534955","article-title":"Molecular profile of subungual melanoma: a melanostrum consortium study of 68 cases reporting Braf, Nras, Kit, and Tert promoter status","volume":"240","author":"Millan-Esteban","year":"2024","journal-title":"Dermatology"},{"issue":"6","key":"10.1016\/j.bcp.2025.117434_b0025","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2023.102038","article-title":"Long term activity of vemurafenib in cancers with braf mutations: the acse basket study for advanced cancers other than Braf(V600)-mutated melanoma","volume":"8","author":"Blay","year":"2023","journal-title":"ESMO Open"},{"key":"10.1016\/j.bcp.2025.117434_b0030","doi-asserted-by":"crossref","first-page":"268","DOI":"10.3389\/fonc.2019.00268","article-title":"Diverse mechanisms of Braf inhibitor resistance in melanoma identified in clinical and preclinical studies","volume":"9","author":"Luebker","year":"2019","journal-title":"Front. Oncol."},{"issue":"9","key":"10.1016\/j.bcp.2025.117434_b0035","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15092607","article-title":"Braf V600-mutated metastatic melanoma and targeted therapy resistance: an update of the current knowledge","volume":"15","author":"Florent","year":"2023","journal-title":"Cancers (Basel)"},{"issue":"40","key":"10.1016\/j.bcp.2025.117434_b0040","doi-asserted-by":"crossref","first-page":"27714","DOI":"10.1074\/jbc.M113.532432","article-title":"Mitogen-activated protein kinase (Mapk) hyperactivation and enhanced nras expression drive acquired vemurafenib resistance in V600e Braf melanoma cells","volume":"289","author":"Lidsky","year":"2014","journal-title":"J. Biol. Chem."},{"issue":"9","key":"10.1016\/j.bcp.2025.117434_b0045","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1038\/s41389-018-0081-3","article-title":"Oncogenic Pi3k\/Akt promotes the step-wise evolution of combination Braf\/Mek inhibitor resistance in melanoma","volume":"7","author":"Irvine","year":"2018","journal-title":"Oncogenesis"},{"issue":"7658","key":"10.1016\/j.bcp.2025.117434_b0050","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1038\/nature22794","article-title":"Rare cell variability and drug-induced reprogramming as a mode of cancer drug resistance","volume":"546","author":"Shaffer","year":"2017","journal-title":"Nature"},{"issue":"10","key":"10.1016\/j.bcp.2025.117434_b0055","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1158\/2159-8290.CD-13-1007","article-title":"The immune microenvironment confers resistance to Mapk pathway inhibitors through macrophage-derived Tnfalpha","volume":"4","author":"Smith","year":"2014","journal-title":"Cancer Discov."},{"key":"10.1016\/j.bcp.2025.117434_b0060","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2019.172621","article-title":"Drug resistance of braf-mutant melanoma: review of up-to-date mechanisms of action and promising targeted agents","volume":"862","author":"Rossi","year":"2019","journal-title":"Eur. J. Pharmacol."},{"issue":"9","key":"10.1016\/j.bcp.2025.117434_b0065","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1002\/cncr.35178","article-title":"Braf\/Mek inhibitor rechallenge in advanced melanoma patients","volume":"130","author":"Van Not","year":"2024","journal-title":"Cancer"},{"issue":"7674","key":"10.1016\/j.bcp.2025.117434_b0070","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1038\/nature24040","article-title":"Pak signalling drives acquired drug resistance to Mapk inhibitors in Braf-mutant melanomas","volume":"550","author":"Lu","year":"2017","journal-title":"Nature"},{"issue":"3","key":"10.1016\/j.bcp.2025.117434_b0075","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.jdermsci.2020.01.013","article-title":"The retinoid derivant ecpirm selectively exhibited anti-proliferation effects in cutaneous T-cell lymphoma via Itk-mediated signaling pathway","volume":"97","author":"Li","year":"2020","journal-title":"J. Dermatol. Sci."},{"issue":"8","key":"10.1016\/j.bcp.2025.117434_b0080","doi-asserted-by":"crossref","first-page":"e38","DOI":"10.1038\/emm.2013.75","article-title":"Phospholipase D inhibitor enhances radiosensitivity of breast cancer cells","volume":"45","author":"Cheol Son","year":"2013","journal-title":"Exp. Mol. Med."},{"issue":"13","key":"10.1016\/j.bcp.2025.117434_b0085","doi-asserted-by":"crossref","first-page":"5677","DOI":"10.1128\/MCB.24.13.5677-5686.2004","article-title":"Phospholipase D elevates the level of Mdm2 and suppresses DNA damage-induced increases in P53","volume":"24","author":"Hui","year":"2004","journal-title":"Mol. Cell Biol."},{"issue":"1","key":"10.1016\/j.bcp.2025.117434_b0090","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1038\/nrc.2015.2","article-title":"DNA damage and the balance between survival and death in cancer biology","volume":"16","author":"Roos","year":"2016","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.bcp.2025.117434_b0095","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1007\/978-3-319-22539-5_4","article-title":"Melanoma: clinical presentations","volume":"167","author":"Kibbi","year":"2016","journal-title":"Cancer Treat. Res."},{"issue":"12","key":"10.1016\/j.bcp.2025.117434_b0100","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1080\/17460441.2020.1795124","article-title":"Preclinical discovery and clinical development of encorafenib for the treatment of melanoma","volume":"15","author":"Okten","year":"2020","journal-title":"Expert Opin. Drug Discov."},{"issue":"5","key":"10.1016\/j.bcp.2025.117434_b0105","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1007\/s40265-018-0884-8","article-title":"Braf and Mek inhibitors: use and resistance in braf-mutated cancers","volume":"78","author":"Sanchez","year":"2018","journal-title":"Drugs"},{"key":"10.1016\/j.bcp.2025.117434_b0110","doi-asserted-by":"crossref","unstructured":"Vander Heiden, M. G., and R. J. DeBerardinis. Understanding the Intersections between Metabolism and Cancer Biology. Cell 168.4 (2017): 657-669. http:\/\/doi.org\/10.1016\/j.cell.2016.12.039.","DOI":"10.1016\/j.cell.2016.12.039"},{"issue":"9","key":"10.1016\/j.bcp.2025.117434_b0115","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1158\/2159-8290.CD-20-0329","article-title":"Changes in aged fibroblast lipid metabolism induce age-dependent melanoma cell resistance to targeted therapy via the fatty acid transporter Fatp2","volume":"10","author":"Alicea","year":"2020","journal-title":"Cancer Discov."},{"issue":"8","key":"10.1016\/j.bcp.2025.117434_b0120","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2020.108421","article-title":"Melanoma persister cells are tolerant to Braf\/Mek inhibitors via Acox1-mediated fatty acid oxidation","volume":"33","author":"Shen","year":"2020","journal-title":"Cell Rep."},{"issue":"9","key":"10.1016\/j.bcp.2025.117434_b0125","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1038\/s42255-023-00861-4","article-title":"Metabolic rewiring induced by ranolazine improves melanoma responses to targeted therapy and immunotherapy","volume":"5","author":"Redondo-Munoz","year":"2023","journal-title":"Nat Metab"},{"issue":"14","key":"10.1016\/j.bcp.2025.117434_b0130","doi-asserted-by":"crossref","first-page":"3806","DOI":"10.1158\/0008-5472.CAN-20-2114","article-title":"Dual covalent inhibition of Pkm and Impdh targets metabolism in cutaneous metastatic melanoma","volume":"81","author":"Zerhouni","year":"2021","journal-title":"Cancer Res."},{"issue":"11","key":"10.1016\/j.bcp.2025.117434_b0135","first-page":"805","article-title":"Phospholipase D and its essential role in cancer","volume":"40","author":"Cho","year":"2017","journal-title":"Mol. Cells"},{"key":"10.1016\/j.bcp.2025.117434_b0140","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1007\/164_2019_320","article-title":"Phospholipase D and choline metabolism","volume":"259","author":"Onono","year":"2020","journal-title":"Handb. Exp. Pharmacol."},{"issue":"6","key":"10.1016\/j.bcp.2025.117434_b0145","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1002\/(SICI)1097-0215(20000315)85:6<882::AID-IJC24>3.0.CO;2-E","article-title":"Changes in Phospholipase D isoform activity and expression in multidrug-resistant human cancer cells","volume":"85","author":"Fiucci","year":"2000","journal-title":"Int. J. Cancer"},{"issue":"1","key":"10.1016\/j.bcp.2025.117434_b0150","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1186\/s13046-024-02988-y","article-title":"Essential role of Pld2 in hypoxia-induced stemness and therapy resistance in ovarian tumors","volume":"43","author":"Munoz-Galvan","year":"2024","journal-title":"J. Exp. Clin. Cancer Res."},{"issue":"18","key":"10.1016\/j.bcp.2025.117434_b0155","doi-asserted-by":"crossref","first-page":"3131","DOI":"10.1128\/MCB.00286-15","article-title":"Phosphatidic acid increases epidermal growth factor receptor expression by stabilizing Mrna decay and by inhibiting lysosomal and proteasomal degradation of the internalized receptor","volume":"35","author":"Hatton","year":"2015","journal-title":"Mol. Cell Biol."},{"issue":"18","key":"10.1016\/j.bcp.2025.117434_b0160","doi-asserted-by":"crossref","DOI":"10.3390\/ijms20184484","article-title":"Long-term vemurafenib exposure induced alterations of cell phenotypes in melanoma: increased cell migration and its association with Egfr expression","volume":"20","author":"Molnar","year":"2019","journal-title":"Int. J. Mol. Sci."},{"issue":"52","key":"10.1016\/j.bcp.2025.117434_b0165","doi-asserted-by":"crossref","first-page":"26823","DOI":"10.1073\/pnas.1911584116","article-title":"Foxa1 upregulation promotes enhancer and transcriptional reprogramming in endocrine-resistant breast cancer","volume":"116","author":"Fu","year":"2019","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"1","key":"10.1016\/j.bcp.2025.117434_b0170","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1038\/ng.730","article-title":"Foxa1 is a key determinant of estrogen receptor function and endocrine response","volume":"43","author":"Hurtado","year":"2011","journal-title":"Nat. Genet."},{"issue":"10","key":"10.1016\/j.bcp.2025.117434_b0175","doi-asserted-by":"crossref","first-page":"17527","DOI":"10.1002\/jcp.28376","article-title":"Resistance to bortezomib in breast cancer cells that downregulate Bim through Foxa1 O-Glcnacylation","volume":"234","author":"Liu","year":"2019","journal-title":"J. Cell. Physiol."},{"issue":"2","key":"10.1016\/j.bcp.2025.117434_b0180","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1172\/JCI122367","article-title":"Targeting Foxa1-mediated repression of Tgf-Beta signaling suppresses castration-resistant prostate cancer progression","volume":"129","author":"Song","year":"2019","journal-title":"J. Clin. Invest."},{"issue":"1","key":"10.1016\/j.bcp.2025.117434_b0185","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1038\/s41392-020-0150-x","article-title":"DNA damage response signaling pathways and targets for radiotherapy sensitization in cancer","volume":"5","author":"Huang","year":"2020","journal-title":"Signal Transduct. Target. Ther."}],"container-title":["Biochemical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295225006999?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295225006999?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T01:35:17Z","timestamp":1769477717000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006295225006999"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":37,"alternative-id":["S0006295225006999"],"URL":"https:\/\/doi.org\/10.1016\/j.bcp.2025.117434","relation":{},"ISSN":["0006-2952"],"issn-type":[{"value":"0006-2952","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Phospholipase D2 regulation by transcription factor FOXA1 promotes the drug resistance of vemurafenib in melanoma cells","name":"articletitle","label":"Article Title"},{"value":"Biochemical Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bcp.2025.117434","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"117434"}}